# Study of Oral Treatments for Hepatitis C

> **NCT02786537** · PHASE4 · COMPLETED · sponsor: **University of Florida** · enrollment: 1275 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** SOF/LDV (sofosbuvir/ledipasvir)
- **DRUG:** PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only)
- **DRUG:** EBR/GZR (elbasvir/grazoprevir)
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT02786537
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2019-06-13
- **Final completion:** 2020-09-02
- **Target enrollment:** 1275 (ACTUAL)
- **Last updated:** 2021-12-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02786537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02786537, "Study of Oral Treatments for Hepatitis C". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02786537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*